PURPOSE: Fifteen independent genetic variants have been implicated in prostate cancer risk by recent genome-wide association studies. However, their association with clinicopathologic features of prostate cancer is uncertain. EXPERIMENTAL DESIGN: We systematically evaluated these 15 variants in 1,563 prostate cancer patients undergoing radical prostatectomy, taking advantage of the uniform tumor stage and grade information available for each of these cases. Associations of these variants with aggressiveness, pathologic Gleason scores, pathologic stage, age at diagnosis, or serum prostate-specific antigen (PSA) levels were tested. RESULTS: After adjusting for multiple testing, none of the single nucleotide polymorphisms was individually or cumulatively associated with aggressiveness or individual clinicopathologic variables of prostate cancer such as Gleason scores, pathologic stage, or age at diagnosis of prostate cancer. The reported risk allele (G) for single nucleotide polymorphism rs2735839 in the KLK3 gene at 19q13 was more frequent in less aggressive prostate cancer patients (0.89) than in more aggressive prostate cancer patients (0.86; nominal P = 0.03) or in controls (0.86; nominal P = 0.04). Considering that this allele was also significantly associated with higher serum PSA levels among controls (nominal P = 0.003), the observed trend of higher frequency of this risk allele between less and more aggressive prostate cancer, or between less aggressive and controls may be due to detection bias of PSA screening. CONCLUSIONS: Prostate cancer risk variants recently discovered from genome-wide case-control association studies are not associated with clinicopathologic variables in this population. Case-case studies are urgently needed to discover genetic variants that predict tumor aggressiveness.
PURPOSE: Fifteen independent genetic variants have been implicated in prostate cancer risk by recent genome-wide association studies. However, their association with clinicopathologic features of prostate cancer is uncertain. EXPERIMENTAL DESIGN: We systematically evaluated these 15 variants in 1,563 prostate cancerpatients undergoing radical prostatectomy, taking advantage of the uniform tumor stage and grade information available for each of these cases. Associations of these variants with aggressiveness, pathologic Gleason scores, pathologic stage, age at diagnosis, or serum prostate-specific antigen (PSA) levels were tested. RESULTS: After adjusting for multiple testing, none of the single nucleotide polymorphisms was individually or cumulatively associated with aggressiveness or individual clinicopathologic variables of prostate cancer such as Gleason scores, pathologic stage, or age at diagnosis of prostate cancer. The reported risk allele (G) for single nucleotide polymorphism rs2735839 in the KLK3 gene at 19q13 was more frequent in less aggressive prostate cancerpatients (0.89) than in more aggressive prostate cancerpatients (0.86; nominal P = 0.03) or in controls (0.86; nominal P = 0.04). Considering that this allele was also significantly associated with higher serum PSA levels among controls (nominal P = 0.003), the observed trend of higher frequency of this risk allele between less and more aggressive prostate cancer, or between less aggressive and controls may be due to detection bias of PSA screening. CONCLUSIONS:Prostate cancer risk variants recently discovered from genome-wide case-control association studies are not associated with clinicopathologic variables in this population. Case-case studies are urgently needed to discover genetic variants that predict tumor aggressiveness.
Authors: Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2006-05-07 Impact factor: 38.330
Authors: Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich Journal: Proc Natl Acad Sci U S A Date: 2006-08-31 Impact factor: 11.205
Authors: Liang Wang; Shannon K McDonnell; Joshua P Slusser; Scott J Hebbring; Julie M Cunningham; Steven J Jacobsen; James R Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau Journal: Cancer Res Date: 2007-04-01 Impact factor: 12.701
Authors: Gianluca Severi; Vanessa M Hayes; Emma J D Padilla; Dallas R English; Melissa C Southey; Robert L Sutherland; John L Hopper; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: Fredrick R Schumacher; Heather Spencer Feigelson; David G Cox; Christopher A Haiman; Demetrius Albanes; Julie Buring; Eugenia E Calle; Stephen J Chanock; Graham A Colditz; W Ryan Diver; Alison M Dunning; Matthew L Freedman; John M Gaziano; Edward Giovannucci; Sue E Hankinson; Richard B Hayes; Brian E Henderson; Robert N Hoover; Rudolf Kaaks; Timothy Key; Laurence N Kolonel; Peter Kraft; Loic Le Marchand; Jing Ma; Malcolm C Pike; Elio Riboli; Meir J Stampfer; Daniel O Stram; Gilles Thomas; Michael J Thun; Ruth Travis; Jarmo Virtamo; Gerald Andriole; Edward Gelmann; Walter C Willett; David J Hunter Journal: Cancer Res Date: 2007-04-01 Impact factor: 12.701
Authors: David J Hernandez; Matthew E Nielsen; Misop Han; Bruce J Trock; Alan W Partin; Patrick C Walsh; Jonathan I Epstein Journal: Urology Date: 2008-03-04 Impact factor: 2.649
Authors: Miia Suuriniemi; Ilir Agalliu; Daniel J Schaid; Bo Johanneson; Shannon K McDonnell; Lori Iwasaki; Janet L Stanford; Elaine A Ostrander Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-04 Impact factor: 4.254
Authors: Brian T Helfand; Kimberly A Roehl; Phillip R Cooper; Barry B McGuire; Liesel M Fitzgerald; Geraldine Cancel-Tassin; Jean-Nicolas Cornu; Scott Bauer; Erin L Van Blarigan; Xin Chen; David Duggan; Elaine A Ostrander; Mary Gwo-Shu; Zuo-Feng Zhang; Shen-Chih Chang; Somee Jeong; Elizabeth T H Fontham; Gary Smith; James L Mohler; Sonja I Berndt; Shannon K McDonnell; Rick Kittles; Benjamin A Rybicki; Matthew Freedman; Philip W Kantoff; Mark Pomerantz; Joan P Breyer; Jeffrey R Smith; Timothy R Rebbeck; Dan Mercola; William B Isaacs; Fredrick Wiklund; Olivier Cussenot; Stephen N Thibodeau; Daniel J Schaid; Lisa Cannon-Albright; Kathleen A Cooney; Stephen J Chanock; Janet L Stanford; June M Chan; John Witte; Jianfeng Xu; Jeannette T Bensen; Jack A Taylor; William J Catalona Journal: Hum Genet Date: 2015-02-26 Impact factor: 4.132
Authors: Jiyoung Ahn; Adam S Kibel; Jong Y Park; Timothy R Rebbeck; Hanna Rennert; Janet L Stanford; Elaine A Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D Mittal; William B Isaacs; Elizabeth A Platz; Richard B Hayes Journal: Clin Cancer Res Date: 2011-02-22 Impact factor: 12.531
Authors: Mark M Pomerantz; Lillian Werner; Wanling Xie; Meredith M Regan; Gwo-Shu Mary Lee; Tong Sun; Carolyn Evan; Gillian Petrozziello; Mari Nakabayashi; William K Oh; Philip W Kantoff; Matthew L Freedman Journal: Cancer Prev Res (Phila) Date: 2011-03-02
Authors: N Pashayan; S W Duffy; S Chowdhury; T Dent; H Burton; D E Neal; D F Easton; R Eeles; P Pharoah Journal: Br J Cancer Date: 2011-04-05 Impact factor: 7.640
Authors: Fredrik E Wiklund; Hans-Olov Adami; Sigun L Zheng; Pär Stattin; William B Isaacs; Henrik Grönberg; Jianfeng Xu Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05 Impact factor: 4.254
Authors: Hemang Parikh; Zuoming Deng; Meredith Yeager; Joseph Boland; Casey Matthews; Jinping Jia; Irene Collins; Ariel White; Laura Burdett; Amy Hutchinson; Liqun Qi; Jennifer A Bacior; Victor Lonsberry; Matthew J Rodesch; Jeffrey A Jeddeloh; Thomas J Albert; Heather A Halvensleben; Timothy T Harkins; Jiyoung Ahn; Sonja I Berndt; Nilanjan Chatterjee; Robert Hoover; Gilles Thomas; David J Hunter; Richard B Hayes; Stephen J Chanock; Laufey Amundadottir Journal: Hum Genet Date: 2009-10-13 Impact factor: 4.132